Smooth muscle-specific Gsα deletion exaggerates angiotensin II-induced abdominal aortic aneurysm formation in mice in vivo

Abstract

Objective:

Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease without an effective pharmaceutical treatment. Genetic studies have proved the involvement of smooth muscle phenotype switch in the development of AAA. The alpha subunit of the heterotrimeric G stimulatory protein (Gsα) mediates receptor-stimulated production of cyclic adenosine monophosphate (cAMP). However, the role of smooth muscle Gsα in AAA formation remains unknown.

Approach and results:

In this study, mice with knockout of smooth muscle-specific Gsα (Gsα^SMKO) were generated by cross-breeding Gsα^flox/flox mice with SM22-CreER^T2 transgenic mice, induced in adult mice by tamoxifen treatment. Gsα deficiency induced a smooth muscle phenotype switch from a contractile to a synthetic state. Mechanically, Gsα deletion reduced cAMP level and increased the level of human antigen R (HuR), which binds with the adenylate uridylate–rich elements of the 3′ untranslated region of Krüppel-like factor 4 (KLF4) mRNA, thereby increasing the stability of KLF4. Moreover, genetic knockdown of HuR or KLF4 rescued the phenotype switch in Gsα-deficient smooth muscle cells. Furthermore, with acute infusion of angiotensin II, the incidence of AAA was markedly higher in ApoE^−/−/Gsα^SMKO than ApoE^−/−/Gsα^flox/flox mice and induced increased elastic lamina degradation and aortic expansion. Finally, the levels of Gsα and SM α-actin were significantly lower while those of HuR and KLF4 were higher in human AAA samples than adjacent nonaneurysmal aortic sections.

Conclusions:

Gsα may play a protective role in AAA formation by regulating the smooth muscle phenotype switch and could be a potential therapeutic target for AAA disease.

1. Introduction

Abdominal aortic aneurysm (AAA) represents the top 20th cause of mortality in the United States and results in about 15,000 deaths per year [1]. In humans > 65 years old, the incidence of AAA is up to 9% [2]. The pathological characteristics of AAA are localized structural deterioration of the aortic wall and progressive aortic dilation [3]. AAA is often accompanied by downregulation of multiple contractile proteins in aortic smooth muscle cells (SMCs) [4,5]. Furthermore, aortic intimal layer injury and inflammatory cell infiltration participate in the aneurysm progression via complicated mechanisms such as cytokine secretion and increased reactive oxygen species levels [3,6]. Finally, vascular collagen and elastin extracellular matrix is thought to undergo degradation by matrix metalloproteinases and contribute to AAA formation [4,7]. However, the detailed mechanisms underlying AAA formation remain unknown.

SMCs have remarkable phenotypic plasticity different from some terminally differentiated cells [8]. The SMC phenotype switch was defined as transformation from a quiescent contractile state to a synthetic state [9]. This process is characterized by the coordinate downregulation of differentiated SMC markers such as SM α-actin (α-SMA), SM22α and SM myosin heavy chain (SMMHC) required for contraction [10]. The SMC phenotype switch is considered to play an important role in the development of cardiovascular diseases such as atherosclerosis and AAA [11–13]. Many studies have identified proteins such as Krüppel-like factor 4 (KLF4) regulating the SMC phenotype switch [14]. Smooth muscle-specific deletion of KLF4 attenuated AAA formation via phenotypic modulation [15]. However, the mechanism that regulates KLF4 expression and the SMC phenotype switch remains unclear.

The alpha-subunit of the stimulatory G protein (Gsα) is expressed in many cell types and is responsible for receptor-stimulated cyclic adenosine monophosphate (cAMP) generation and activation of the downstream signaling pathways [16]. For example, in rat aortic SMCs, cAMP could decrease the expression of human antigen R (HuR), which is an mRNA binding protein and increase the stability of target mRNAs [17]. Gsα dysfunction is involved in many diseases. The endothelium-specific Gsα knockout mice were embryonic lethal due to abnormal vessel structure and serious bleeding [18]. However, mice overexpressing a dominant negative Gsα-mutant in heart leads to decreased β-adrenergic responsiveness and is protective against ISO-induced hypertrophy [19]. In our recent report, we found that Gsα could regulate intestinal smooth muscle contraction in mice [20]. However, the roles of Gsα in the SMC phenotype switch and AAA formation are undefined.

In the present study, we used mice with SM22-CreER^T2–mediated Gsα knockout to demonstrate that Gsα deficiency in smooth muscle exacerbates angiotensin II (AngII)-induced AAA formation by regulating the SMC phenotype switch.

2. Materials and methods

2.1. Animals

Gsα^flox/flox mice were kindly provided by Dr. Lee S. Weinstein (generation /characterization of this mouse strain described previously [21]). SM22-CreER^T2 mice expressing a tamoxifen-inducible Cre recombinase under control of the SM22 promoter [22] were kindly provided by Dr. Robert Feil. ApoE^−/− mice were from Vital River Laboratories (Distributor of Jackson Laboratory, Beijing, China). All mice were C57BL/6 J background. Mice with smooth muscle-specific Gsα knockout (Gsα^SMKO) were generated as follows. Gsα^flox/flox mice were cross-bred with SM22-CreER^T2 mice to produce Gsα^flox/flox/Cre⁺ mice, which were injected with tamoxifen (1 mg/day) intraperitoneally for 5 consecutive days at age 8 weeks to generate Gsα^SMKO mice. ApoE^−/−/Gsα^SMKO double knockout mice were generated by crossing Gsα^flox/flox/Cre⁺ mice with ApoE^−/− mice, induced in adult mice by tamoxifen treatment. For AngII-induced AAA, after 2 weeks of tamoxifen injection, male ApoE^−/−/Gsα^SMKO and ApoE^−/−/Gsα^flox/flox mice were infused with AngII (1000 ng/kg/min) via mini-osmotic pumps (Alzet, Model 2004, DURECT Corp., Cupertino, CA). Blood pressure was monitored to confirm effective AngII. The status of mice was observed and Kaplan-Meier curves were plotted during the experiment. Mice were sacrificed and aortic aneurysmal segments were harvested after 28 days. All experiments were conducted in accordance with the guidelines of the Animal Care and Use Committee of Shandong University.

2.2. Statistical analysis

All statistical analyses involved using GraphPad Prism 7.0 (GraphPad Software, San Diego, CA). Two groups were compared by Student t-test and > 2 groups by 2-way ANOVA and Bonferroni post-tests. Data are presented as mean ± SEM. P < .05 was considered statistically significant.

Detailed descriptions of other unmentioned materials, methods, and experimental procedures are available in Supplemental Materials and Methods.

3. Results

3.1. Generation and analysis of Gsα^SMKO mice

To elucidate the biological significance of Gsα expression in vascular SMCs in vivo, Gsα^flox/flox mice were cross-bred with SM22-CreER^T2 mice expressing a tamoxifen-activated Cre recombinase to generate Gsαflox/+/Cre⁺ mice. These were further intercrossed to obtain Gsα^flox/flox/Cre⁺ mice, which were injected with tamoxifen at age 8 weeks to generate Gsα^SMKO mice. Littermate Gsα^flox/flox/Cre⁻ mice with the same dose of tamoxifen were controls.

To confirm smooth muscle-specific Gsα deletion in Gsα^SMKO mice, immunofluorescence was used to detect Gsα expression in aortas. SMCs were detected by α-SMA staining. Gsα expression was significantly lower in the smooth muscle layer from Gsα^SMKO than control aortas (Fig. 1A). The protein and mRNA levels of Gsα were significantly decreased in aortas from Gsα^SMKO mice (Fig. 1B and C). Gsα plays its physiological roles mainly via generating receptor-stimulated cAMP, so we measured cAMP level in aortas. As expected, cAMP level was significantly reduced after Gsα knockout (Fig. 1D), which further confirmed effective Gsα deletion in Gsα^SMKO mice. However, there was no significant difference for the Gsα expression in the macrophage and vascular adventitial fibroblasts between CTR and Gsα^SMKO mice (Supplementary Fig. 1E).

Fig. 1.

Identification of Gsα deletion in aortic smooth muscle from Gsα^SMKO mice. A, Representative immunofluorescence staining of Gsα, α-SMA and 4′,6-diamidino-2-phenylindole (DAPI) for nuclei in abdominal aortas from control and Gsα^SMKO mice. IgG was labeled as the negative control. Scale bar, 200 μm. B, Western blot analysis of aortic Gsα protein expression from control and Gsα^SMKO mice and quantification (n = 5). *P < 0.05 vs control. C, Quantitative RT-PCR analysis of aortic Gsα mRNA level in control and Gsα^SMKO mice (n = 5). **P < 0.01 vs control. D, Aortic cAMP level in control and Gsα^SMKO mice (n = 6). *P < 0.05 vs control. Data are mean ± SEM.

Gsα deletion did not affect the blood pressure. However, the heart rate, the body weight and ejection function were lower in the Gsα^SMKO mice (Supplementary Table 1). Besides, there was no significant difference in the aortic media thickness and SMC size between control and Gsα^SMKO mice (Supplementary Fig. 1G–I). Thus, VSMC-specific Gsα knockout didn’t alter aortic medial SMC content in mice. In addition, we detected the mRNA levels of some cytokines in heart tissues from the Gsα^SMKO and control mice. The mRNA levels of IL-17C, ICAM-1, IL-1β and TGF-β were increased significantly in Gsα^SMKO mice compared with control mice (Supplementary Fig. 5E).

3.2. Gsα deficiency induces the SMC phenotype switch

We next explored whether Gsα modulates the expression of smooth-muscle marker genes. Abdominal aortas from control and Gsα^SMKO mice were isolated; immunohistochemistry revealed significantly reduced level of α-SMA and SMMHC (marker of SMC contractile phenotype) in Gsα^SMKO than control aortas with higher level of Vimentin and Osteopontin (marker of SMC synthetic phenotype) (Fig. 2A, B); Gsα deletion in SMCs decreased the protein and mRNA levels of α-SMA and SMMHC; in the meanwhile, increased those of Vimentin and Osteopontin (Fig. 2C–E). Besides, Gsα knockout also reduced SM22 and Calponin expression (Supplementary Fig. 1A). Thus, Gsα deficiency induced the SMC phenotype switch from a contractile to a synthetic state. Moreover, Gsα deletion increased the phosphorylation of P65 (the marker of NF-κB activation) (Supplementary Fig. 1F) and the levels of SMC derived cytokines such as TGF-β1, IL-6, E-selectin, IL-17C, ICAM-1, TNF-α and CCL-2 (Supplementary Fig. 1B). Gsα deficiency also increased the expression of MMP2, fibronectin, collagen I and collagen III (Supplementary Fig. 1A).

Fig. 2.

Gsα deficiency induces SMC phenotype switch. A, Representative immunochemical staining of α-SMA, SMMHC, Vimentin and Osteopontin in abdominal aortas from control and Gsα^SMKO mice. IgG was labeled as the negative control. Scale bar, 50 μm. B, Quantification of IHC (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001 vs control. C, Western blot analysis of α-SMA, SMMHC, Osteopontin and Vimentin protein expression in control and Gsα^SMKO mice. D, Quantification of Western blot (n = 5). *P < 0.05, ***P < 0.001 vs control. E, Quantitative RT-PCR analysis of aortic α-SMA, SMMHC, Osteopontin and Vimentin mRNA levels in control and Gsα^SMKO mice (n = 5). *P < 0.05 vs control. Data are mean ± SEM.

3.3. Gsα deficiency increases KLF4 and HuR expression

KLF4 is known as a key factor required for the SMC phenotype switch, and its deletion attenuated AAA formation [13]. Our results also suggested that Gsα could regulate the SMC phenotype switch, so we next determined whether KLF4 level was changed by Gsα deficiency. KLF4 protein level was significantly elevated in Gsα^SMKO aortas (Fig. 3A and B), which was further confirmed by RT-PCR and immunohistochemistry (Fig. 3C–E). Thus, Gsα deficiency increased KLF4 expression.

Fig. 3.

Gsα deficiency increases KLF4 and HuR expression. A, Western blot analysis of protein levels of KLF4 and HuR in primary control and Gsα-deficient SMCs and B, quantification (n = 5). *P < 0.05, **P < 0.01 vs control. C, Quantitative analysis of KLF4 and HuR mRNA levels in primary control and Gsα-deficient SMCs (n = 5). *P < 0.05, **P < 0.01 vs control. D, Representative immunochemical staining for KLF4 and HuR in abdominal aortas from control and Gsα^SMKO mice. IgG was labeled as the negative control. E, Quantification of IHC (n = 5). **P < 0.01 vs control. Data are mean ± SEM.

Previous study showed that cAMP could inhibit HuR expression [17]. In the SMCs, both 8-Br-cAMP (the cAMP analog) and Forskolin (adenylate cyclase activator) could decrease HuR expression (Supplementary Fig. 5A), suggesting that cAMP is required for HuR downregulation. Moreover, H-89 (PKA inhibitor) increased the HuR expression (Supplementary Fig. 5B), suggesting that PKA is required for HuR downregulation. Thus, cAMP/PKA could reduce HuR expression in SMCs. In addition, Gsα deletion in smooth muscle reduced cAMP level (Fig. 1D) and HuR protein level was increased after Gsα deletion (Fig. 3A and B), which was also confirmed by RT-PCR and immunohistochemistry (Fig. 3C–E). Hence, Gsα deficiency could increase KLF4 and HuR expression in mouse aortic smooth muscle.

3.4. KLF4 is the HuR target gene

HuR is an RNA-binding protein that regulates the stability of adenylate uridylate (AU)-rich element (ARE)-containing transcripts. We examined the 3′ untranslated region (UTR) of KLF4 mRNA to assess whether KLF4 may be a target of HuR and found 3 conserved AREs in the 3′ UTR (Fig. 4A), which suggested that HuR may bind with KLF4 mRNA and regulate its expression.

Fig. 4.

KLF4 is the HuR target gene. A, Schematic representations of predicted adenylate uridylate (AU)-rich elements (AREs) in the 3′ untranslated region (UTR) of KLF4 mRNA. ORF: Open Reading Frame. B, RNA immunoprecipitation (IP) with anti-HuR antibody or control IgG. Cyclooxygenase-2 was the positive control. 1&5: No template PCR control. 2&6: IgG RNA IP. 3&7: Anti-HuR RNA IP. 4&8: 10% Input. C, Primary SMCs were infected with adenovirus expressing GFP or HuR for 24 h, then treated with actinomycin D (5 μg/mL). Quantified RT-PCR analysis of KLF4 mRNA level (n = 5). D, SMCs were treated with Vehicle (DMSO) or HuR inhibitor, CMLD-2 (20 μM) for 24 h, then underwent western blot analysis to detect KLF4 protein level (n = 4). **P < 0.01 vs Vehicle. Data are mean ± SEM.

RNA immunoprecipitation with anti-HuR antibody or control IgG showed that HuR could bind with KLF4 mRNA (Fig. 4B). Cyclooxygenase-2, a known target of HuR, was used as a positive control in this assay. To examine the effect of HuR on the stability of endogenous KLF4 mRNA, primary aortic SMCs were infected with adenovirus expressing GFP or HuR and then treated with actinomycin D, a transcriptional inhibitor. The half-life of KLF4 mRNA was increased from 0.75 to 1.25 h after HuR overexpression (Fig. 4C), so HuR enhanced KLF4 mRNA stability. Furthermore, CYLD2, an HuR inhibitor, significantly reduced KLF4 expression (Fig. 4D). Thus, KLF4 is the target of HuR, which could bind to and stabilize endogenous KLF4 mRNA transcripts, thus elevating KLF4 protein level.

3.5. Gsα deletion induces the SMC phenotype switch via the HuR/KLF4 pathway

To detect whether Gsα deletion induces the SMC phenotype switch via the HuR/KLF4 pathway, primary aortic SMCs from control or Gsα^SMKO mice were transfected with HuR siRNA to knock down HuR expression. HuR knockdown suppressed the levels of KLF4 and Vimentin and increased that of α-SMA in control and Gsα-deficient SMCs (Fig. 5A and B). Hence, HuR-mediated KLF4 expression may participate in the Gsα deletion–induced SMC phenotype switch. To further confirm the role of KLF4 in the process, KLF4 siRNA was used to transfect SMCs. As expected, KLF4 knockdown increased α-SMA expression and decreased Vimentin level in control and Gsα-deficient SMCs (Fig. 5C and D), so KLF4 inhibition could rescue the SMC phenotype switch caused by Gsα knockout. Hence, Gsα deletion induced the SMC phenotype switch via the HuR/KLF4 pathway.

Fig. 5.

Gsα deletion induces SMC phenotype switch via the HuR/KLF4 pathway. A, Primary control and Gsα-deficient SMCs were transfected with control siRNA or HuR siRNA for 48 h followed by western blot analysis and B, quantified (n = 5). *P < 0.05 vs Control+CTR siRNA. #P < 0.05 vs Gsα^SMKO + CTR siRNA. C, Primary control and Gsα-deficient SMCs were transfected with control siRNA or KLF4 siRNA for 48 h followed by western blot analysis and D, quantified (n = 5). *P < 0.05, **P < 0.01 vs Control+CTR siRNA. #P < 0.05 vs Gsα^SMKO + CTR siRNA. Data are mean ± SEM.

3.6. Smooth muscle-specific Gsα deletion exaggerates AngII-induced AAA formation

Because Gsα regulates the SMC phenotype switch, which plays an important role in the development of AAA [13], we sought to determine whether Gsα expression changed during AAA formation. ApoE^−/− mice were infused with saline or AngII for 28 days to induce AAA; Gsα expression was significantly reduced in abdominal aortas with AngII infusion as compared with saline infusion (Fig. 6A and Supplementary Fig. 2A). Ang II infusion also decreased cAMP levels (Supplementary Fig. 2C).

Fig. 6.

Smooth muscle-specific Gsα deletion exaggerates AngII-induced AAA formation. A, Representative immunochemical staining of Gsα in abdominal aortas from ApoE^−/− mice infused with Saline or AngII (1000 ng/kg/min) for 28 days and quantification (n = 5). IgG was labeled as the negative control. **P < 0.01 vs Saline. B, Male adult ApoE^−/−/Gsα^flox/flox and ApoE^−/−/Gsα^SMKO mice were infused with saline or AngII (1000 ng/kg/min) for 28 days. Representative photographs showed macroscopic features of aneurysms induced by AngII. C, Data represent percentage incidence of AAAs in ApoE^−/−/Gsα^flox/flox (saline n = 8, AngII n = 35) and ApoE^−/−/Gsα^SMKO (saline n = 8, AngII n = 35) mice. *P < 0.05 for AngII-infused ApoE^−/−/Gsα^SMKO compared with ApoE^−/−/Gsα^flox/flox mice. D, Maximal abdominal aortic diameters in mice with different treatment (n = 7). **P < 0.01 vs ApoE^−/−/Gsα^flox/flox + AngII. E, Representative HE, VVG staining, and immunochemical staining of CD68, MMP2 and 4-HNE in AAA and their quantification (n = 4). **P < 0.01, ***P < 0.001. Scale bar, 200 μm for HE, MMP2 and 4-HNE, 100 μm for VVG and CD68. IgG was labeled as the negative control. F, Grade of elastin degradation in aortic wall (n = 7). *P < 0.05 for AngII-infused ApoE^−/−/Gsα^SMKO compared with ApoE^−/−/Gsα^flox/flox mice. G. Kaplan-Meier curves represent percentage survival of AngII-infused ApoE^−/−/Gsα^flox/flox and ApoE^−/−/Gsα^SMKO mice (n = 30). Data are mean ± SEM.

To determine the role of smooth muscle-specific Gsα deletion in the development of AAA, ApoE^−/−/Gsα^flox/flox and ApoE^−/−/Gsα^SMKO mice were generated, the levels of Gsα protein and cAMP were decreased in ApoE^−/−/Gsα^SMKO mice (Supplementary Fig. 2B and D). Consistent with data in C57BL/6 J background, the levels of HuR, KLF4 and Vimentin were increased, while the levels of α-SMA and SM22 were decreased in ApoE^−/−/Gsα^SMKO mice compared with ApoE^−/−/Gsα^flox/flox mice (Supplementary Fig. 5D). In addition, the mRNA levels of TGF-β1, IL-6, E-selectin, IL-17C, ICAM-1, TNF-α and CCL-2 were elevated in aortas from ApoE^−/−/Gsα^SMKO mice compared with ApoE^−/−/Gsα^flox/flox mice (Supplementary Fig. 5G). With AngII or saline infusion, the mRNA levels of CCL-2, E-selectin, TNF-α and ICAM-1 were increased in ApoE^−/−/Gsα^SMKO mice compared with ApoE^−/−/Gsα^flox/flox mice (Supplementary Fig. 6B). Thus Gsα knockout could also increase the proinflammatory phenotype in ApoE^−/− background.

Male adult ApoE^−/−/Gsα^flox/flox and ApoE^−/−/Gsα^SMKO mice were infused with saline or AngII for 28 days, AngII infusion could reduce the cAMP levels (Supplementary Fig. 5F) and PKA activity (Supplementary Fig. 5C) in both ApoE^−/−/Gsα^flox/flox and ApoE^−/−/Gsα^SMKO mice. AAA was defined as ≥50% enlargement of the external diameter of the suprarenal aorta compared to aortas from saline-infused control mice. Gsα knockout in smooth muscle did not affect the blood pressure in saline and AngII-infused groups (Supplementary Table 2). Gross morphology of aortas did not differ between saline-infused ApoE^−/−/Gsα^flox/flox and ApoE^−/−/Gsα^SMKO mice (Fig. 6B); however, with AngII infusion, the incidence of AAA in ApoE^−/−/Gsα^SMKO mice was increased compared with in ApoE^−/−/Gsα^flox/flox mice (31 [88.6%] of 35 ApoE^−/−/Gsα^SMKO mice vs 22 [62.8%] of 35 ApoE^−/−/Gsα^flox/flox mice, Fig. 6C). Kaplan-Meier curves demonstrated that smooth muscle-specific Gsα deletion increased mortality rate due to aneurysm rupture in both AngII-induced models of aneurysm formation (Fig. 6G). Additionally, the maximal diameter of the abdominal aorta was significantly higher in AngII-infused ApoE^−/−/Gsα^SMKO than ApoE^−/−/Gsα^flox/flox mice (Fig. 6B and D). Gsα deficiency also increased the incidence of thoracic aortic aneurysm (TAA) with AngII infusion (13 [37.1%] of 35 ApoE^−/−/Gsα^SMKO mice vs 5 [14.3%] of 35 ApoE^−/−/Gsα^flox/flox mice). However, Gsα deficiency did not affect the atherosclerotic plaque area in AngII-induced ApoE^−/−Gsα^flox/flox and ApoE^−/−Gsα^SMKO mice (Supplementary Fig. 1C–D).

Hematoxylin and eosin (HE) and Verhoff-Van Gieson (VVG) staining revealed that AngII infusion caused positive remodeling of the abdominal aorta, breakdown of the aortic media and adventitia and destruction, and discontinuity of elastin fibers in ApoE^−/−/Gsα^flox/flox mice (Fig. 6E and Supplementary Fig. 2E). These pathological changes induced by AngII were largely exaggerated in ApoE^−/−/Gsα^SMKO mice (Fig. 6E and F). Additionally, the matrix metalloproteinase 2 (MMP2) level and inflammatory cell infiltration as determined by CD68 of the AAA were elevated in AngII-infused ApoE^−/−/Gsα^SMKO than ApoE^−/−/Gsα^flox/flox mice (Fig. 6E and Supplementary Fig. 2E). However, Gsα deficiency did not affect the level of reactive oxygen species (ROS) as determined by 4-hydroxynonenal (4-HNE) immunostaining in the AAA (Fig. 6E and Supplementary Fig. 2E). Moreover, Gsα deficiency increased Vimentin and Osteopontin expression with AngII infusion compared with control groups (Supplementary Fig. 6A), which confirms the important role of SMC phenotype switch in the AAA progression. Taken together, Gsα deficiency in SMCs aggravated the AngII-induced AAA formation.

3.7. The levels of Gsα and α-SMA are reduced while those of HuR and KLF4 are increased in human AAA samples

To establish the clinical relevance of Gsα/HuR/KLF4 signaling and AAA formation, we further examined the levels of Gsα, HuR, KLF4 and α-SMA in human AAA samples. Human AAA tissues and their control adjacent aortic sections without aneurysm were obtained from patients undergoing open surgery (Supplementary Fig. 5H). As expected, the levels of Gsα and α-SMA were significantly lower in human AAA sections than adjacent nonaneurysmal aortic sections (Fig. 7A–B, Supplementary Fig. 3 and Fig. 4). Meanwhile, both HuR and KLF4 were significantly upregulated in human AAA samples (Fig. 7A–B, Supplementary Fig. 3 and Fig. 4), which indicates the important role of Gsα/HuR/KLF4 signaling in the development of AAA.

Fig. 7.

The levels of Gsα and α-SMA are reduced while those of HuR and KLF4 are increased in human AAA samples. A, Representative immunohistochemical staining of Gsα, HuR, KLF4 and α-SMA in human AAA tissues and adjacent normal aortas and B, quantification (n = 7). *P < 0.05, **P < 0.01 vs Control. Data are mean ± SEM. C, Diagram for the protective role of Gsα in AngII-induced AAA formation via HuR/KLF4. AC, adenylyl cyclase.

4. Discussion

In this study, to explore the functions of Gsα in SMCs in vivo, we generated tamoxifen-inducible Gsα^flox/flox/SM22-CreER^T2 mice, which are smooth muscle-specific Gsα knockout mice, by using a tamoxifen-activated Cre recombinase method. Deletion of Gsα in aortic SMCs resulted in an SMC phenotype switch, with decreased expression of contractile marker α-SMA and increased expression of the synthetic marker Vimentin in aortas. Mechanically, Gsα deficiency reduced cAMP level and increased the level of HuR, which bound with KLF4 mRNA and enhanced its stability (Fig. 7C). Moreover, Gsα was downregulated in mouse and human AAA samples; smooth muscle-specific Gsα deletion exaggerated AngII-induced AAA formation in vivo. Taken together, our results reveal that Gsα plays a protective role in the development of AAA by inhibiting the HuR/KLF4-mediated SMC phenotype switch.

Increasing evidence indicates that Gsα plays important roles in cell proliferation, apoptosis, differentiation and metabolism [23,24]. To detect the functions of Gsα in vivo, many tissue-specific Gsα knockout mice have been generated. For example, adipose-specific Gsα knockout mice showed a lean phenotype with impaired cold tolerance and increased diet-induced thermogenesis [25]. Pancreas-specific Gsα deficiency led to increased pancreatic alpha-cell proliferation and decreased pancreatic beta-cell proliferation [26]. Recent research showed that multiple human diseases are related to somatic GNAS mutations encoding the Gsα. Constitutively activating Gsα mutations were extensively detected in McCune-Albright syndrome and parosteal osteosarcoma, whereas heterozygous GNAS mutations causing decreased expression of Gsα resulted in Albright hereditary osteodystrophy [23]. Transgenic mice overexpressing cardiac Gsα exhibited increased cardiac contractility in response to β-adrenergic receptor stimulation. However, these mice developed cardiomyopathy with aging [27–29], suggesting that overexpression of Gsα has a detrimental effect on cardiac function. In this study, we demonstrated that Gsα has a protective role on vascular structure, which indicates that Gsα plays different roles in the different tissues. Moreover, consideration about the synthetic phenotype of Gsα-deficient smooth muscle cells, Gsα deletion might increase the angiogenesis and reduce the vascular resistance in the small vessels. In our previous study, Gsα deficiency impaired intestinal smooth muscle contraction [20], which affect their food intake. Thus, Gsa^SMKO mice exhibited the phenotype of lower body weight. Moreover, the increased inflammation in the heart of Gsα^SMKO mice may contribute to the phenotype of lower heart rate and ejection fraction. However, the reason of the cardiac dysfunction needs to be explored in the further study.

A phenotype switch is the characteristic reaction of SMCs in response to adverse stimuli such as biological factors, extracellular matrix components and chemico-physical factors [30]. The SMC phenotype switch affects the progression of many diseases such as atherosclerosis and AAA [12,14,15]. The mechanism of the phenotype switch is complicated and involves multiple factors. Myocardin and caveolin-3 were both identified as the guardians of a vascular smooth muscle contractile phenotype [31,32], whereas miR-143/145 and KLF4 promoted the SMC phenotype switch from a contractile to a synthetic state [12,14,33]. Although various data demonstrated that KLF4 is a key molecule regulating the SMC phenotype switch, the regulation of KLF4 expression is still unclear. Recent study showed that Sp1 could bind to the KLF4 gene promoter to increase its expression [34]. In this study, we demonstrated that HuR could bind with KLF4 mRNA and increase its mRNA stability, so KLF4 mRNA stability is regulated by HuR. This discovery uncovers a novel mechanism of KLF4 gene regulation and also broadens the biological functions of HuR. Our study demonstrated that Gsα and HuR participate in regulating the aortic SMC phenotype switch. Because HuR has a wide range of target mRNAs, the HuR/KLF4 may not be the single mechanism in AAA. Previous study showed that HuR could increase the stability of MMP2 and MMP9 mRNAs [35]. Moreover, some inflammatory cytokines such as CCL-2 and IL-6 are the targets of HuR [36,37]. Thus, HuR may participate in the AAA progression through regulating some different pathways. Additionally, there are many PKA substrates and PKA regulated genes, many of which might modulate the phenotype of Gsα-deficient mice. Future study will be performed to explore their roles.

Gsα deficiency in SMCs also caused increased inflammation in aortas. Inflammatory factors such as IL-6, ICAM-1, CCL-2 and TNF-α were up-regulated significantly in Gsα^SMKO compared with control mice. However, the possible mechanisms were still unclear. Previous studies show that HuR regulates the expression of many inflammatory cytokines including IL-6, ICAM-1, CCL-2, IL-17C and TNF-α through binding to their mRNAs [36–39]. Thus, the increased inflammation caused by Gsα deficiency may be resulted from increased HuR expression. Moreover, Gsα deletion increased the phosphorylation of p65, the aberrant activation of NF-κB pathway is another potential mechanism of increased inflammation.

The mechanism underlying AAA is complicated; many kinds of cells (SMCs, macrophages, endothelial cells, etc.) and various elements (inflammation, cell apoptosis, extracellular matrix, etc.) participate in this process. Here, we show that smooth muscle-specific Gsα deletion increased AAA formation by promoting the SMC phenotype switch, which was consistent with the mechanism found in smooth muscle-specific KLF4-knockout mice [14]. Another study directly demonstrated that loss of α-SMA increased the sensitivity to AngII by increasing Agtr1a level, which was established to drive AAA formation [40]. Thus, the SMC phenotype switch may be one of the most important mechanisms of AAA formation. Moreover, there is no effective clinical pharmacological therapy to prevent or suppress AAA development. Some studies explored the effect of cAMP agonist on the aneurysm. Cilostazol, a selective inhibitor of cAMP phosphodiesterase 3, could increase cellular cAMP and suppress the development of AAA in the mouse and rat models [41,42], which was consistent with the conclusion in this study.

In conclusion, we have established a causative relation between smooth-muscle Gsα deficiency and AAA formation in vivo and identified the protective role of Gsα in AngII-triggered AAA. The identification of Gsα expression in AngII-triggered AAA and in human patients with AAA suggests that Gsα downregulation might be a reason for AAA formation, and the agents that activate the Gsα signaling pathway may have therapeutic potential for AAA and other cardiovascular diseases.

Abbreviations:

AAA

Abdominal aortic aneurysm

AngII

angiotensin II

ARE

adenylate uridylate-rich element

α-SMA

SM α-actin

cAMP

cyclic adenosine monophosphate

Gsα

alpha-subunit of the stimulatory G protein

Gsα^SMKO

smooth muscle-specific Gsα knockout

HuR

human antigen R

KLF4

Krüppel-like factor 4

SMCs

Smooth muscle cells

UTR

untranslated region